Zobrazeno 1 - 10
of 183
pro vyhledávání: '"Benoit You"'
Autor:
Vahan Kepenekian, Frédéric Bibeau, Anthony Dohan, Juliette Fontaine, Olivier Bouché, Peggy Dartigues, Jean-Baptiste Delhorme, Diane Goéré, François Quenet, Gerlinde Averous, Clarisse Eveno, Benoit You, Pascal Rousset, Jean-Marc Gornet, Laurent Villeneuve, Pascale Mariani, Olivier Glehen, Marc Pocard
Publikováno v:
Digestive and Liver Disease. 54:30-39
Introduction This document is a summary of the French Intergroup guidelines regarding the management of appendicular epithelial tumors (AT) and pseudomyxoma peritonei (PMP) published in March 2020, available on the website of the French Society of Ga
Autor:
Naoual Bakrin, Julien Péron, Mohammad Alyami, Isabelle Bonnefoy, Vahan Kepenekian, Nazim Benzerdjeb, Olivier Glehen, Pascal Rousset, Laurent Villeneuve, Benoit You
Publikováno v:
Annals of Surgical Oncology. 29:2104-2113
Diffuse malignant peritoneal mesothelioma (DMPM) is an aggressive primary peritoneal neoplasia. At diagnosis, few patients are eligible for a recommended cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Among neoadju
Autor:
Tifenn Lharidon, J C Théry, Marie-Ange Mouret Reynier, Philippe Barthélémy, Thomas Filleron, Francesco Del Piano, Marc Debled, Christelle Levy, Monica Arnedos, Alexandra Jacquet, Xavier Tchiknavorian, Florence Dalenc, Alicia Tran-Dien, Anthony Gonçalves, Jean-Marc Ferrero, Fabrice Andre, Mario Campone, Ivan Bièche, Benjamin Verret, Ingrid Garberis, Amélie Lusque, Florence Coussy, Etienne Rouleau, C. Lefeuvre-Plesse, Marie-Paule Sablin, Alice Mege, Marta Jimenez, William Jacot, Benoit You, Thomas Bachelot, Nicolas Isambert, Julien Adam
Publikováno v:
Nature Medicine. 27:250-255
The impact of single-agent antibodies against programmed death-ligand 1 (PD-L1) as maintenance therapy is unknown in patients with metastatic breast cancer. The SAFIR02-BREAST IMMUNO substudy included patients with human epidermal growth factor recep
Autor:
J. Grenier, Isabelle Moullet, Jérôme Meunier, Brigitte Lucas, Raymond Despax, Adina Marti, Jean-Marc Ferrero, Fabien Brocard, Alain Lortholary, Benoit You, A.M. Savoye, Jérôme Martin-Babau, Anne-Claire Hardy-Bessard, Florian Clatot, George Emile
Publikováno v:
Breast, Vol 54, Iss, Pp 256-263 (2020)
The Breast : Official Journal of the European Society of Mastology
The Breast : Official Journal of the European Society of Mastology
Purpose Combining bevacizumab with paclitaxel significantly improves progression-free survival (PFS) versus paclitaxel alone in HER2-negative metastatic breast cancer (MBC). Eribulin is active and tolerable in pretreated MBC. To assess whether eribul
Autor:
Emma V. Jones, Joon Rhee, Jérôme Alexandre, Zhongwu Lai, L Opincar, Matthew G Krebs, Yeon Hee Park, Jean Pierre Delord, Antoine Italiano, Anna M. L. Coenen-Stass, Seock-Ah Im, Sara Bastian, Sophie Postel-Vinay, Sakshi Gulati, Susan M. Domchek, Ding Wang, Saiama N. Waqar, Haiyan Gao, Benoit You, P. Herbolsheimer, M. Lanasa, Helen K. Angell, Iwanka Kozarewa, Vidalba Rocher-Ros, Bella Kaufman
Publikováno v:
Domchek, S M, Postel-Vinay, S, Im, S-A, Park, Y H, Delord, J-P, Italiano, A, Alexandre, J, You, B, Bastian, S, Krebs, M G, Wang, D, Waqar, S N, Lanasa, M, Rhee, J, Gao, H, Rocher-Ros, V, Jones, E V, Gulati, S, Coenen-Stass, A, Kozarewa, I, Lai, Z, Angell, H K, Opincar, L, Herbolsheimer, P & Kaufman, B 2020, ' Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA) : an open-label, multicentre, phase 1/2, basket study ', The Lancet. Oncology, vol. 21, no. 9, pp. 1155-1164 . https://doi.org/10.1016/S1470-2045(20)30324-7
BACKGROUND: Poly (ADP-ribose) polymerase inhibitors combined with immunotherapy have shown antitumour activity in preclinical studies. We aimed to assess the safety and activity of olaparib in combination with the PD-L1-inhibitor, durvalumab, in pati
Autor:
Philippe Follana, Pierre Combe, Eric Pujade-Lauraine, Alexandra Leary, Patrick Robelin, Gilles Freyer, Michel Fabbro, Nathalie Bonichon-Lamichhane, Christophe Desauw, Olivier Colomban, Christophe Louvet, Jean-Emmanuel Kurtz, Gwenael Ferron, M. Leheurteur, Annick Chevalier-Place, Benoit You, Gaëtan de Rauglaudre, Isabelle Ray-Coquard, Jean-Pierre Lotz, Sophie Abadie-Lacourtoisie, Florence Joly, Francesco Del Piano, Michel Tod
Publikováno v:
Clinical Cancer Research. 26:4625-4632
Purpose: In patients with ovarian cancer receiving neoadjuvant chemotherapy, the first-line treatment success will depend on both the tumor-primary chemosensitivity and the completeness of interval debulking surgery (IDS). The modeled CA-125 ELIMinat
Autor:
Mathilde Cancel, Oana Pop, Alain Lortholary, C.B. Levaché, Daniel Pissaloux, Magali Provansal, Elsa Kalbacher, Rémy Largillier, Amélie Anota, Audrey Lardy-Cleaud, Jérôme Meunier, Christophe Louvet, Anne-Claire Hardy-Bessard, Aurélie Houlier, Marie-Ange Mouret-Reynier, Fabien Brocard, Benoit You, Anne Floquet, Cyril Abdeddaim, Aude-Marie Savoye, Isabelle Ray-Coquard, Alain Zannetti, Laurence Venat-Bouvet, Isabelle Treilleux, Olivier Tredan, Jean-Sebastien Frenel
Publikováno v:
Gynecologic Oncology
Gynecologic Oncology, 2022, 164 (1), pp.18-26. ⟨10.1016/j.ygyno.2021.09.024⟩
Gynecologic Oncology, 2022, 164 (1), pp.18-26. ⟨10.1016/j.ygyno.2021.09.024⟩
Objective To evaluate the efficacy and safety of regorafenib versus tamoxifen in platinum-sensitive ovarian cancer biological recurrence, defined by CA-125 increase without radiological (RECIST criteria) or symptomatic evidence of progression. Patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::442e0efad461a61c2ee12df093873312
https://hal.archives-ouvertes.fr/hal-03868128
https://hal.archives-ouvertes.fr/hal-03868128
Publikováno v:
SSRN Electronic Journal.
5530 Background: ICON8 phase III trial did not show improvement in PFS or OS with first-line weekly dose-dense chemotherapy in EOC. This analysis evaluated the impact of tumor intrinsic primary chemosensitivity (assessed with modeled CA-125 ELIMinati
Autor:
Michel Tod, Pierre-Adrien Bolze, Olivier Colomban, Rémi Tod, Benoit You, Michael J. Seckl, Gilles Freyer, R. Osborne, Kathleen Dekeister, Touria Hajri, François Golfier, Jean-Pierre Lotz, Jérôme Massardier
Publikováno v:
Cancer Chemotherapy and Pharmacology. 86:15-24
In a low-risk gestational trophoblastic neoplasia (GTN) treated with methotrexate (MTX), the modeled hCG (human chorionic gonadotropin) residual concentration (hCGres), calculated with NONMEM program® (NM) during the first 50 treatment days, is a pr
Autor:
Lone Sunde, Kirsty Balanchandran, Minke Frijstein, Georgia Mangili, Sileny Han, Miguel Henriques Abreu, Nataliya Tsip, Anneke M. Westermann, Vilmos Fulop, Franziska Siegenthaler, Michael J. Seckl, Manuela Undurraga, John Coulter, Anne Hills, Angela Salerno, Kamaljit Singh, Lotte Boog, Jacob Korach, Nelleke Ottevanger, Jérôme Massardier, Ulrika Joneborg, Eva Maria Roes, Frédéric Goffin, Luisa Skupin, Fernando Manuel Ribeiro Gomes, Alice Bergamini, Jane Ireson, Benoit You, Catriona Kenneally, Miroslav Korbel, Saša Kadija, Vildana Finci, Isa Niemann, Sarah Delcominette, Antonio Casado, Gloria Marquina, Pierre Adrien Bolze, Grzegorz Szewczyk, François Golfier, Nienke E. van Trommel, Naveed Sarwar, Raffaella Cioffi, Cantù Maria Grazia, Patrick Chien, John Tidy, Christianne A.R. Lok, Gitta Turowski, Yalck K. Eysbouts, Su Harma, Ginette Rosseel, Ulrike Meyer-Hamme, Erika Utracka, Jocelyne Attia, Mehmet Harma, Olesya Solheim, Matthew C Winter, Jean Pierre Lotz, Vesna Kesic, Sophie Patrier, Muge Harma, Janne Kaern, Magdalena Miedzińska, Sinan Ozalp, Eva-Maria Grischke, Amit Mayer, Leigh Bowman, Emelie Wallin, Hind Hamad Elmalik, Leon F.A.G. Massuger
Publikováno v:
European Journal of Cancer, 130, pp. 228-240
European journal of cancer (Oxford, England, 130, 228-240. Elsevier Limited
European Journal of Cancer, 130, 228-240
European journal of cancer (Oxford, England, 130, 228-240. Elsevier Limited
European Journal of Cancer, 130, 228-240
Background and aim Gestational trophoblastic disease (GTD) is a heterogeneous group of disorders characterised by abnormal proliferation of trophoblastic tissue. Since GTD and its malignant sequel gestational trophoblastic neoplasia (GTN) are rare di